<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211522</url>
  </required_header>
  <id_info>
    <org_study_id>AG035117-01A1</org_study_id>
    <secondary_id>101082</secondary_id>
    <nct_id>NCT01211522</nct_id>
  </id_info>
  <brief_title>The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study</brief_title>
  <acronym>MIND-USA</acronym>
  <official_title>MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological
      Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium
      in vulnerable critically ill patients. We and others have shown that delirium is an
      independent predictor of more death, longer stay, higher cost, and long-term cognitive
      impairment often commensurate with moderate dementia. The rapidly expanding aging ICU
      population is especially vulnerable to develop delirium, with 7 of 10 medical and surgical
      ICU patients developing this organ dysfunction. Antipsychotics are the first-line
      pharmacological agents recommended to treat delirium, and over the past 30 years they gained
      widespread use in hospitalized patients globally prior to adequate testing of efficacy and
      safety for this indication. Haloperidol, the most commonly chosen antipsychotic, is used by
      over 80% of ICU doctors for delirium, while atypical antipsychotics are prescribed by 40%.
      Antipsychotics safety concerns include lethal cardiac arrhythmias, extrapyramidal symptoms,
      and the highly publicized increased mortality associated with their use in non-ICU geriatric
      populations. The overarching hypothesis is that administration of typical and atypical
      antipsychotics—haloperidol and ziprasidone, in this case—to critically ill patients with
      delirium will improve short- and long-term clinical outcomes, including days alive without
      acute brain dysfunction (referred to as delirium/coma-free days or DCFDs) over a 14-day
      period; 30-day, 90-day, and 1-year survival; ICU length of stay; incidence, severity, and/or
      duration of long-term neuropsychological dysfunction; and quality of life at 90-day and
      1-year. To test these hypotheses, the MIND-USA Study will be a multi-center, double-blind,
      randomized, placebo-controlled investigation in 561 critically ill, delirious
      medical/surgical ICU patients who are (a) on mechanical ventilation or non-invasive positive
      pressure ventilation or (b) in shock on vasopressors. In each group (haloperidol,
      ziprasidone, and placebo), 187 patients will be enrolled and treated until delirium has
      resolved for 48 hours or to 14 days (whichever occurs first) and followed for 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary and secondary outcomes of the MIND-USA investigation will be analyzed both
      according to the individual comparisons by group of &quot;haloperidol treated&quot; vs. &quot;placebo
      treated&quot; and &quot;ziprasidone treated&quot; vs. &quot;placebo treated&quot; and also the combined grouping of
      both antipsychotics (&quot;haloperidol plus ziprasidone treated&quot; patients vs. &quot;placebo treated&quot;
      patients). In the latter third of the study, as a result of a paper by Patel S et al AJRCCM
      2014 about rapidly reversible delirium (RRD), we considered modifying delirium assessments to
      detect those who might convert from CAM-ICU positive to negative following SATs, but we
      estimated that only 5 patients per arm would be in this category (and indeed &lt;20 per arm in
      the entire study using the 10% rate published by Patel). With such low numbers and the
      assurance that through randomization we would have all groups analyzed similarly according to
      the study drug assignment, we elected not to alter the protocol and not to conduct subgroup
      analyses according to RRD status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2011</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium/Coma-free Days (DCFDs)</measure>
    <time_frame>14 days</time_frame>
    <description>Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30-day and 90-day</time_frame>
    <description>Deaths within the specified timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium Duration</measure>
    <time_frame>14 days</time_frame>
    <description>Duration of delirium during the intervention period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Torsades de Pointes</measure>
    <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Extrapyramidal Symptoms</measure>
    <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neuroleptic Malignant Syndrome</measure>
    <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Liberation From Mechanical Ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to successful liberation from mechanical ventilation, where &quot;successful&quot; indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Final ICU Discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Days from randomization to final, successful ICU discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive. &quot;ICU discharge&quot; is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ICU Readmission</measure>
    <time_frame>90 days after first ICU discharge</time_frame>
    <description>Days from first ICU discharge to next ICU readmission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Days from randomization to successful hospital discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">566</enrollment>
  <condition>Delirium</condition>
  <condition>Impaired Cognition</condition>
  <condition>Long Term Psychologic Disorders</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haloperidol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziprasidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adult patients (≥18 years old)

          2. in a medical and/or surgical ICU

          3. on mechanical ventilation or non-invasive positive pressure ventilation (NIPPV),
             and/or requiring vasopressors due to shock

          4. delirious (according to the CAM-ICU)

        Exclusion Criteria:

          1. Rapidly resolving organ failure criteria, indicated by planned immediate
             discontinuation of mechanical ventilation, NIPPV, and/or vasopressors at the time of
             screening for study enrollment

          2. Pregnancy or breastfeeding (negative pregnancy test required prior to enrollment of
             female patients of childbearing age)

          3. Severe dementia or neurodegenerative disease, defined as either impairment that
             prevents the patient from living independently at baseline or IQCODE &gt;4.5, measured
             using a patient's qualified surrogate, mental illness requiring long-term
             institutionalization, acquired or congenital mental retardation, Parkinson's disease,
             Huntington's disease, and/or coma or another severe deficit due to structural brain
             disease such as stroke, intracranial hemorrhage, cranial trauma, intracranial
             malignancy, anoxic brain injury, or cerebral edema.

          4. History of torsades de pointes, documented baseline QT prolongation (congenital long
             QT syndrome), or QTc &gt;500 ms at screening due to refractory electrolyte abnormalities,
             other drugs, or thyroid disease

          5. Ongoing maintenance therapy with typical or atypical antipsychotics

          6. History of neuroleptic malignant syndrome (NMS), haloperidol allergy, or ziprasidone
             allergy

          7. Expected death within 24 hours of enrollment or lack of commitment to aggressive
             treatment by family or the medical team (e.g., likely withdrawal of life support
             measures within 24 hours of screening)

          8. Inability to obtain informed consent from an authorized representative within 72 hours
             of meeting all inclusion criteria, i.e., developing qualifying organ dysfunction
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Wesley Ely, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver Health/University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204-4507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical College-Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7248</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Health System</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-9472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Wes Ely</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Ziprasidone</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Sedation</keyword>
  <keyword>Long-term cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01211522/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01211522/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haloperidol</title>
          <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="P2">
          <title>Ziprasidone</title>
          <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haloperidol</title>
          <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="B2">
          <title>Ziprasidone</title>
          <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="184"/>
            <count group_id="B4" value="566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="51" upper_limit="69"/>
                    <measurement group_id="B2" value="61" lower_limit="50" upper_limit="69"/>
                    <measurement group_id="B3" value="59" lower_limit="52" upper_limit="67"/>
                    <measurement group_id="B4" value="60" lower_limit="51" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ARDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Airway protection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD/asthma/other pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHF/MI/arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis/liver failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizures/neurologic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delirium/Coma-free Days (DCFDs)</title>
        <description>Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Delirium/Coma-free Days (DCFDs)</title>
          <description>Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O3" value="7" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Deaths within the specified timeframe</description>
        <time_frame>30-day and 90-day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Deaths within the specified timeframe</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-day mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90-day mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delirium Duration</title>
        <description>Duration of delirium during the intervention period</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Delirium Duration</title>
          <description>Duration of delirium during the intervention period</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Torsades de Pointes</title>
        <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Torsades de Pointes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Extrapyramidal Symptoms</title>
        <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Extrapyramidal Symptoms</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neuroleptic Malignant Syndrome</title>
        <time_frame>14 days plus 4-day post-study drug period (if longer than 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neuroleptic Malignant Syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Liberation From Mechanical Ventilation</title>
        <description>Days from randomization to successful liberation from mechanical ventilation, where &quot;successful&quot; indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Liberation From Mechanical Ventilation</title>
          <description>Days from randomization to successful liberation from mechanical ventilation, where &quot;successful&quot; indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Final ICU Discharge</title>
        <description>Days from randomization to final, successful ICU discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive. &quot;ICU discharge&quot; is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Final ICU Discharge</title>
          <description>Days from randomization to final, successful ICU discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive. &quot;ICU discharge&quot; is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to ICU Readmission</title>
        <description>Days from first ICU discharge to next ICU readmission.</description>
        <time_frame>90 days after first ICU discharge</time_frame>
        <population>Time to ICU readmission reported among those who were readmitted to the ICU</population>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to ICU Readmission</title>
          <description>Days from first ICU discharge to next ICU readmission.</description>
          <population>Time to ICU readmission reported among those who were readmitted to the ICU</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge</title>
        <description>Days from randomization to successful hospital discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haloperidol</title>
            <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge</title>
          <description>Days from randomization to successful hospital discharge, where &quot;successful&quot; indicates that discharge was followed by at least 48 hours alive.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8" upper_limit="22"/>
                    <measurement group_id="O2" value="12" lower_limit="8" upper_limit="21"/>
                    <measurement group_id="O3" value="13" lower_limit="8" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the period when the patients were receiving a trial drug or placebo and for 4 days after discontinuation, we assessed the patients for side effects. We also collected clinical outcomes data until hospital discharge or up to 90 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Haloperidol</title>
          <description>Haloperidol
Haloperidol: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="E2">
          <title>Ziprasidone</title>
          <description>Ziprasidone
Ziprasidone: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Torsades de pointes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Extrapyramidal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Oversedation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>E Wesley Ely</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>‭(615) 936-3395‬</phone>
      <email>wes.ely@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

